Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro

Open Access

Peer-reviewed

Research Article

Jennifer D. Könitzer ,

* E-mail: jennifer.koenitzer@boehringer-ingelheim.com

Affiliation Boehringer Ingelheim, Division Research Germany, Immune Modulation and Biotherapeutics Discovery, Biberach/Riß, Germany
⨯
Annette Sieron,

Affiliation Boehringer Ingelheim, Biopharma Operations Germany, Biberach/Riß, Germany
⨯
Angelika Wacker,

Affiliation Boehringer Ingelheim, Bioprocess and Pharmaceutical Development Germany, Biberach/Riß, Germany
⨯
Barbara Enenkel

Affiliation Boehringer Ingelheim, Bioprocess and Pharmaceutical Development Germany, Biberach/Riß, Germany
⨯

Reader Comments (0)

Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cross-linking
Is the Subject Area "Cross-linking" applicable to this article?

Thanks for your feedback.
Antibody isotypes
Is the Subject Area "Antibody isotypes" applicable to this article?

Thanks for your feedback.
Antibody therapy
Is the Subject Area "Antibody therapy" applicable to this article?

Thanks for your feedback.
Cysteine
Is the Subject Area "Cysteine" applicable to this article?

Thanks for your feedback.
Cell binding
Is the Subject Area "Cell binding" applicable to this article?

Thanks for your feedback.
Flow cytometry
Is the Subject Area "Flow cytometry" applicable to this article?

Thanks for your feedback.
Protein engineering
Is the Subject Area "Protein engineering" applicable to this article?

Thanks for your feedback.